Implementation Strategies for Monitoring Adherence in Real Time
The objective of this project is to identify effective strategies to help patients with lung cancer manage side effects and achieve optimal adherence to oral targeted therapies. To achieve this objective, we will evaluate the effect of a novel, bidirectional conversational agent, compared to usual care, on adherence to oral targeted therapies using a two-arm randomized controlled trial, and explore how multilevel factors impact the acceptability and effectiveness of this strategy by collecting qualitative and quantitative data from clinicians and patients.
Checked against the public recordLast updated Mar 4, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Supportive Care
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- Abramson Cancer Center at Penn Medicine
- Interventions being studied
- Device: Conversational Agent/Chatbot; Other: Usual Care
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Adult patient (age \> 18 years) with NSCLC at UPHS who is receiving one of the following nine oral therapies: afatinib, erlotinib, dacomitinib, gefitinib, osimertinib, alectinib, brigatinib, crizotinib, or lorlatinib. * Patient possession of a mobile device that can send/receive SMS texts * Ability to respond to questions and engage with "Penny" in English * Ability to provide informed consent to participate in the study * Approval from the patient's medical oncologist to be approached Exclusion Criteria: * Inability to respond to questions and engage with "Penny" in English * Inability or unwillingness to provide informed consent to participate in the study * Inability to engage with SMS text-messaging platform * Concurrent enrollment in a therapeutic clinical trial * Taking more than one oral targeted therapy or concurrent chemotherapy during the study window * Lack of approval from the patient's oncologist
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of PennsylvaniaPhiladelphia, Pennsylvania
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 4, 2026. Always confirm current availability with the study team.